Swiss National Bank raised its holdings in Hill-Rom Holdings, Inc. (NYSE:HRC) by 4.4% during the first quarter, HoldingsChannel reports. The institutional investor owned 122,600 shares of the medical technology company’s stock after buying an additional 5,200 shares during the period. Swiss National Bank’s holdings in Hill-Rom were worth $12,978,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. BlackRock Inc. boosted its position in shares of Hill-Rom by 3.5% during the 4th quarter. BlackRock Inc. now owns 6,350,899 shares of the medical technology company’s stock valued at $562,371,000 after acquiring an additional 215,770 shares in the last quarter. Vanguard Group Inc raised its stake in shares of Hill-Rom by 0.6% in the third quarter. Vanguard Group Inc now owns 5,916,827 shares of the medical technology company’s stock worth $558,549,000 after acquiring an additional 34,369 shares during the last quarter. Oregon Public Employees Retirement Fund raised its stake in shares of Hill-Rom by 8,755.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 2,308,056 shares of the medical technology company’s stock worth $26,000 after acquiring an additional 2,281,991 shares during the last quarter. Bank of Montreal Can raised its stake in shares of Hill-Rom by 5.0% in the first quarter. Bank of Montreal Can now owns 1,724,410 shares of the medical technology company’s stock worth $182,547,000 after acquiring an additional 81,956 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Hill-Rom by 27.0% in the fourth quarter. Bank of New York Mellon Corp now owns 1,038,521 shares of the medical technology company’s stock worth $91,961,000 after acquiring an additional 220,981 shares during the last quarter. Institutional investors own 81.31% of the company’s stock.

Shares of HRC traded down $0.08 on Wednesday, reaching $103.64. 3,830 shares of the company’s stock were exchanged, compared to its average volume of 509,816. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.69 and a quick ratio of 1.27. The company has a market cap of $6.90 billion, a price-to-earnings ratio of 21.80, a price-to-earnings-growth ratio of 1.78 and a beta of 0.90. Hill-Rom Holdings, Inc. has a 12 month low of $81.82 and a 12 month high of $108.68.

Hill-Rom (NYSE:HRC) last issued its earnings results on Friday, April 26th. The medical technology company reported $1.14 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.11 by $0.03. Hill-Rom had a net margin of 7.93% and a return on equity of 21.30%. The firm had revenue of $714.20 million during the quarter, compared to the consensus estimate of $705.59 million. During the same quarter in the prior year, the firm earned $1.05 earnings per share. The business’s quarterly revenue was up .5% on a year-over-year basis. As a group, analysts expect that Hill-Rom Holdings, Inc. will post 5.05 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Friday, June 21st will be paid a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.81%. The ex-dividend date is Thursday, June 20th. Hill-Rom’s payout ratio is presently 17.68%.

A number of equities analysts have weighed in on the stock. Zacks Investment Research raised shares of Hill-Rom from a “hold” rating to a “buy” rating and set a $103.00 target price for the company in a research note on Thursday, June 6th. ValuEngine raised shares of Hill-Rom from a “hold” rating to a “buy” rating in a research note on Tuesday. Barclays boosted their target price on shares of Hill-Rom from $103.00 to $108.00 and gave the stock an “equal weight” rating in a research note on Monday, April 15th. Finally, Needham & Company LLC reissued a “buy” rating and set a $116.00 price target on shares of Hill-Rom in a research note on Monday, March 11th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Hill-Rom currently has an average rating of “Buy” and a consensus target price of $108.00.

TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2019/06/12/swiss-national-bank-has-12-98-million-holdings-in-hill-rom-holdings-inc-nysehrc.html.

Hill-Rom Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

See Also: What is a support level?

Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.